COMPARISON OF ENTERIC-COATED ASPIRIN TABLETS BY DIFFERENT PRODUCERS: DISSOLUTION TEST RESULTS

1. Lanas A: Cyclo-oxygenase-1/cyclo-oxygenase-2 non selective nonsteroidal anti-inflammatory drugs: Epidemiology of gastrointestinal events// Dig Liver Dis 2001;33 Suppl 2: S29-34.

2. Roderick PJ, Wilkes HC, Meade TW: The gastrointestinal toxicity of aspirin: An overview of randomised controlled trials// Br J Clin Pharmacol 1993;35:219-226.

3. Tarnawski A, Stachura J, Gergely H. et al.: Gastric microvascular endothelium: A major target for aspirin-induced injury and arachidonic acid protection. An ultrastructural analysis in the rat// Eur J Clin Invest 1990;20:432-440.

4. Kelly JP, Kaufman DW, Jurgelon JM, et al.: Risk of aspirinassociated major upper-gastrointestinal bleeding with enteric-coated or buffered product // Lancet 1996;348:1413-1416.

5. Sharland M, on behalf of the SPS: The use of antibacterials in children: A report of the specialist advisory committee on antimicrobial resistance (sacar) paediatric subgroup// J Antimicrob Chemother 2007;60: i15-26.

6. Fries JF, Williams CA, Bloch DA. et al.: Nonsteroidal antiinflammatory drug-associated gastropathy: Incidence and risk factor models// Am J Med 1991;91:213-222.

7. Kulkarni SP, Alexander KP, Lytle BD, et al.: Long-term adherence with cardiovascular drug regimens // Am Heart J 2006;151:185-191.

8. Abbate A, Fusaro M, Burzotta F, et al.: A systematic review and metaanalysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease// Eur Heart J 2006;27:2667-2674.

9. Dietz R, Rauch B: Leitlinie zur diagnose und behandlung der chronischen koronaren herzerkrankung der deutschen gesellschaft fur kardiologie-herz und kreislaufforschung (dgk) // Z Kardiol 2003;92:501-521.